BPC-157 and Blood Pressure: What Research Shows

One of the most well-established side effects linked with BPC-157 concerns blood pressure. In contrast to many side effects described by users that do not have any scientific backing as yet, the effects of bpc 157 on blood pressure can be directly traced to its interaction with the nitric oxide system. This does not mean that these effects can be considered proven in humans, but makes them more likely to have biological basis. In this article below, we take a look at what animal studies indicate, what the users mention and why those taking blood pressure medications should be aware. For broader information, visit our full BPC-157 risks breakdown.

BPC-157 and Blood Pressure - The Research

Why Blood Pressure Changes Are Reported

BPC-157 has an effect on the systems of regulation of vascular tone. According to research conducted in rats, BPC-157 affects the pathway involving nitric oxide which is directly responsible for controlling dilatation and constriction of the blood vessels. Nitric oxide is one of the most important vasodilators in the human body. When the levels of nitric oxide increase, the vessels dilate and blood pressure gets lower. Accordingly, if nitric oxide is interfered with, the vessels will constrict.

A 2025 safety review covering decades of BPC-157 research confirmed the peptide's interaction with NO-mediated pathways in multiple animal models. No controlled human study has measured bpc 157 blood pressure effects directly.

The Nitric Oxide Pathway

How BPC-157 Interacts with NO Systems in Animals

Rodent experiments conducted showed the link between BPC-157 and the NO system. A 2017 study showed that BPC-157 interacts with the NO system in rats, influencing the results in situations where NO activity is manipulated. The peptide can oppose the effect of the NO synthase inhibitors (which triggers an increase in blood pressure through the blocking of NO synthesis) and of the NO donors (which allows lowering blood pressure via saturating the body with NO).

The workings of the mechanism are likely related to the influences of BPC-157 on endothelial NO synthase (eNOS) expression. In compromised tissue, the peptide induced vasodilation through NO to contribute to blood flow and healing. Whether the same endothelial mechanism works with healthy human tissue in normal dosages is unclear.

Vasodilation and Blood Pressure in Rat Models

Through the rat model with hypertension induced by an experiment, BPC-157 was able to regulate the blood pressure to normal levels. In models made with low blood pressure through inhibitors, BPC-157 was also able to raise the blood pressure. This fact does point out the distinction of BPC-157 from regular vasodilators like nitroglycerin which can only lower blood pressure. However, it should be made clear that this was done in laboratory conditions with precise dosages of the drugs in animals. The rats used in the experiment did have hypertension due to medications, not any real pathology of the blood pressure system.

A general review of BPC-157 research confirmed these vascular findings while noting the complete absence of human cardiovascular data.

What Users Report

Blood Pressure Drops After Administration

According to the reports from users in forums, one of the side effects commonly associated with bpc 157 is decrease in blood pressure which occurs shortly after subcutaneous injection. The users have mentioned that they felt dizzy, warm and flushed half an hour after the treatment. There are very few reports of the blood pressure readings during these periods, but those are in favor of the results of the research of the NO pathway.

Individuals having a low baseline blood pressure are more prone to experiencing the impacts of this peptide. Participants with regular or above-average blood pressure do not seem to experience substantial variations. This trend can also be observed in the rats' symmetrical behavior, which was shown to behave in such a way, where the peptide has the strongest impact.

Dizziness as a Related Symptom

Dizziness ranks among the top five self-reported BPC-157 side effects, and it likely shares the same vascular mechanism as blood pressure shifts. A pharmacokinetics study in rats and dogs found a plasma half-life under 30 minutes, which aligns with user reports that dizziness is transient and resolves quickly. The short duration of these episodes suggests a direct pharmacological effect rather than a lasting change in cardiovascular function. For a detailed breakdown of dizziness and other common reactions, see our page on BPC-157 headache, nausea and fatigue.

People on Blood Pressure Medication

Theoretical Additive Effects

Educators have made it clear that BPC-157 has not been studied with any anti-hypertensive drug. Although the tinsel is theoretical, it is pharmacologically valid. If BPC-157 achieves its effect through NO, and if a person is already on a drug which also works through NO, the side effects could add up. Examples of anti-hypertensive drugs that act through NO or that influence muscular tone include ACE inhibitors, calcium antagonists, nitrates and alpha-blockers.

According to reports, the medications which are already associated with the risk of orthostatic hypotension, when people experience a sudden fall in blood pressure on the standing up, pose the greatest danger. In case BPC-157 enhances this drop with even a slight level, the woman could experience a transition from occasionally feeling dizzy when getting up to almost losing consciousness. There are several reports from the users describing this situation even though no medically validated cases have been recorded. Our drug interactions page elaborates on this and other remediation issues extensively.